Introduction#
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced that it has submitted amended claims for its U.S. patent application related to its intranasal drug delivery platform. This move aims to enhance the company's intellectual property protection.
Expanded Patent Claims#
The amended claims extend beyond the core mucoadhesive composition, which refers to substances that help medications stick to mucosal surfaces. They now include drug delivery systems and methods of use. Specifically, the claims involve compositions made of sulfated polysaccharide polymers and other polymeric components that create a uniform film when they come into contact with the mucosal tissues in the nasal cavity.
Technology Benefits#
This intranasal platform is designed to improve the effectiveness of medications. It aims to increase the time that drugs stay in contact with mucosal tissues, which can enhance their absorption into the body. The technology also focuses on forming a controlled film on these surfaces, making it compatible with various types of drugs.
Company Overview and Financials#
Tomer Izraeli, CEO of Polyrizon, emphasized that the submission of these amended claims is a significant step in strengthening the company's patent portfolio. Despite a market capitalization of $30 million and a stock price increase of 171% over the past six months, Polyrizon remains unprofitable. The company has more cash than debt but is rapidly using its financial resources. As of December 31, 2025, Polyrizon reported cash and cash equivalents of approximately $17.5 million.
In addition to its patent developments, Polyrizon is in discussions with the FDA regarding its PL-14 allergy blocker and has submitted a Pre-Request for Designation for its PL-16 viral blocker. The company also announced a recent funding initiative expected to generate around $3.5 million.